Alexiou, S.; Mavrovounis, G.; Christodoulopoulos, G.; Perifanou, S.; Saloustros, E.
CDK4/6 Inhibitors Plus Endocrine Therapy in Early-Stage HR+/HER2− Breast Cancer: Updated Meta-Analysis of Phase III Trials. Cancers 2025, 17, 3538.
https://doi.org/10.3390/cancers17213538
AMA Style
Alexiou S, Mavrovounis G, Christodoulopoulos G, Perifanou S, Saloustros E.
CDK4/6 Inhibitors Plus Endocrine Therapy in Early-Stage HR+/HER2− Breast Cancer: Updated Meta-Analysis of Phase III Trials. Cancers. 2025; 17(21):3538.
https://doi.org/10.3390/cancers17213538
Chicago/Turabian Style
Alexiou, Stamatia, Georgios Mavrovounis, Georgios Christodoulopoulos, Stamatia Perifanou, and Emmanouil Saloustros.
2025. "CDK4/6 Inhibitors Plus Endocrine Therapy in Early-Stage HR+/HER2− Breast Cancer: Updated Meta-Analysis of Phase III Trials" Cancers 17, no. 21: 3538.
https://doi.org/10.3390/cancers17213538
APA Style
Alexiou, S., Mavrovounis, G., Christodoulopoulos, G., Perifanou, S., & Saloustros, E.
(2025). CDK4/6 Inhibitors Plus Endocrine Therapy in Early-Stage HR+/HER2− Breast Cancer: Updated Meta-Analysis of Phase III Trials. Cancers, 17(21), 3538.
https://doi.org/10.3390/cancers17213538